Stay On Top of Emerging Hot Topics
PCI, patients, data and debate drove the conversation at this year's largest interventional cardiology conference. We've collected insights from acclaimed experts to help keep you in the know and ready to address new clinical challenges.
With these brief clips, discover the latest insights to address today's challenges and create optimal outcomes for your patients.
Complex PCI Case
Watch Dr. Jaikirshan Khatri from the Cleveland Clinic share a case highlighting his "go to" wires for complex lesions.
The Latest on the Short DAPT Trial
Learn from global PI Dr. Roxana Mehran about the XIENCE Short DAPT program, including the XIENCE 90 and XIENCE 28 Global clinical trials.
OCT Imaging in PCI Symposium
A clip from the "CHIP Guided by OCT" Symposium led by Drs. Ziad Ali, Richard Shlofmitz, Ulf Landmesser, and Jonathon Hill.
Comparison Among Polymers
Learn from Dr. Renu Virmani about the performance of the XIENCE fluoropolymer in the human body and its performance relative to other stent surfaces.
Hear From Experts
The skill sets required to deliver solutions across a range of complex patients requires skill sets that we currently don't train very well. Dr. James Spratt
FAME 2, 3-Year Data
FFR is the only physiological index that has demonstrated clinical benefits compared to medical therapy alone with substantially lower follow-up costs through 3 years1-3
PCI + Medical Therapy is superior to MT alone in functionally Significant lesions (FFR ≤ .80) using Abbott's PressureWire™1
Despite lower initial costs in the medical therapy alone group, there is no cost benefit at three years1
1. Fearon et al. (2017). 3-year follow up of the FAME 2 trial. TCT. 2. De Bruyne et al. (2012). FAME 2 1-year follow-up. NEJM, 367 (11). 3. De Bruyne et al. (2014). FAME 2 2-year follow-up. NEJM, 371 (13).
Registry arm is for FFR > 0.80, while the randomized portion of MT and PCI are for FFR ≤ 0.80.
The ORBITA trial evaluated the effectiveness of PCI vs. a sham procedure in reducing angina in patients with stable ischemic heart disease.
In the primary endpoint, which was a difference in exercise time increment at six weeks, there was no significant difference between PCI and placebo. In the secondary endpoint of heart performance (defined as peak stress wall motion index score), PCI significantly improved over sham treatment.
Some, like Dr. Gregg Stone, were critical of the patients enrolled in the trial:
About 27% of the patients we'd all agree shouldn't have had the angioplasty because they have no ischemia
Dr. Gregg Stone
I think what this study gives us is the opportunity in this cohort—single vessel coronary disease—to have an informed consent process with our patients
Dr. Rasha Al-Lamee
Al-Lamee, R. ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease. TCT 2017
What are top cardiologists tweeting about these days?
See below for a list of hot topics on the minds of physicians at this year's conference.
Top 10 Tweeted Topics
by Interventional Cardiologists at TCT2017